6 Stocks Poised For Potential Acquisition In The Next 12 Months, According To Goldman Sachs, Including A 200% YTD Gainer - ( AACT ) , Walt Disney ( NYSE:DIS )
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. The bank reported that the total dollar value of M&A deals has risen 29% year-over-year, with deal volumes in 2025 climbing 8%. The bank projects an additional 15% increase in new ...
Mineralys Therapeutics, Inc. ( MLYS ) is a Great Momentum Stock: Should You Buy?
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Here's what needs to happen for these high flyers to continue soaring.
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps
A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one thing is certain.
What Makes Mineralys Therapeutics, Inc. ( MLYS ) a Strong Momentum Stock: Buy Now?
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ...
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Bruker ( NASDAQ:BRKR ) , Alkermes ( NASDAQ:ALKS )
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday. Shares of Bruker Corp BRKR fell sharply in pre-market trading after the company announced a $600 million public offering. Bruker shares tumbled 9.8% to $29.98 in the pre-market ...
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Alset ( NASDAQ:AEI ) , Bollinger Innovations ( NASDAQ:BINI )
Shares of Alphabet Inc. GOOGL GOOG rose sharply in pre-market trading after a U.S. judge issued a sealed decision in the Google online search monopoly case. U.S. District Judge Amit Mehta on Tuesday ruled Google will not be required to divest its Android operating system or sell off Google ...
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc. ( Nasdaq: MLYS ) , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ( CKD ) , obstructive sleep apnea ( OSA ) ...
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - Mineralys Therapeutics ( NASDAQ:MLYS )
RADNOR, Pa., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc.
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Apollo Asset Management ( NYSE:APO ) , Air Lease ( NYSE:AL )
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Air Lease Corporation AL rose sharply during Tuesday's session after the aircraft lessor said it will be acquired by a newly formed Dublin-based holding company backed by Sumitomo Corp.
Nasdaq Down 1%; Signet Jewelers Earnings Top Views - Celularity ( NASDAQ:CELU ) , CARISMA Therapeutics ( NASDAQ:CARM )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.64% to 45,255.26 while the NASDAQ fell 1.04% to 21,232.05. The S&P 500 also fell, dropping, 0.87% to 6,404.13. Energy shares jumped by ...
Nasdaq Down 1%; Signet Jewelers Earnings Top Views - Celularity ( NASDAQ:CELU ) , CARISMA Therapeutics ( NASDAQ:CARM )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.64% to 45,255.26 while the NASDAQ fell 1.04% to 21,232.05. The S&P 500 also fell, dropping, 0.87% to 6,404.13. Energy shares jumped by ...
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket - ALT5 Sigma ( NASDAQ:ALTS ) , CARISMA Therapeutics ( NASDAQ:CARM )
Shares of Carisma Therapeutics, Inc. CARM rose sharply in pre-market trading after the company announced it will receive a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix. Carisma Therapeutics shares jumped 133.4% to $0.5019 in the pre-market trading ...
Wall Street Analysts Believe Mineralys Therapeutics, Inc. ( MLYS ) Could Rally 149.66%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
Mineralys Therapeutics, Inc. ( MLYS ) Upgraded to Buy: Here's Why
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Mineralys Therapeutics, Inc. ( MLYS ) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 154.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ProKidney Stock Shoots Up Over 8% After Hours After Staggering 515% Rally On Wednesday - ProKidney ( NASDAQ:PROK )
ProKidney PROK Class A stock experienced a surge of 8.58% in its after-hours trading, continuing its climb of over 500% during regular trading on Tuesday. What Happened: Following the release of positive results from its Phase 2 trial, the after-hours trading of ProKidney stock saw an increase of ...
Mineralys Therapeutics Announces Journal of the American Medical Association ( JAMA ) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
- The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension ...
Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Mineralys Therapeutics ( NASDAQ:MLYS )
Lorundrostat led to significant reductions in systolic blood pressure and UACR in CKD patients. Adverse events were low, with 3% discontinuing during lorundrostat vs. 2% on placebo. Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 Days - Get The Details Now
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Core Natural Resources ( NYSE:CNR ) , Coinbase Global ( NASDAQ:COIN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Carey MacRury initiated coverage on Gold Royalty Corp.
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection ( ESH 2025 )
- Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting ...
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection ( ESH 2025 ) - Mineralys Therapeutics ( NASDAQ:MLYS )
- Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting -
Here's Why Mineralys Therapeutics, Inc. ( MLYS ) is a Great Momentum Stock to Buy
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 07, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc. ( Nasdaq: MLYS ) , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease ( CKD ) , obstructive sleep apnea ( OSA ) and other diseases driven by ...
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine ( NEJM )
- Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression ...
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo ( ACC.25 )
- Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction ( p=0.001 ) , assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile ...
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
RADNOR, Pa., March 17, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc. ( Nasdaq: MLYS ) , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease ( CKD ) , obstructive sleep apnea and other diseases driven by dysregulated ...
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo - Mineralys Therapeutics ( NASDAQ:MLYS )
RADNOR, Pa., March 17, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc.
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Lazard ( NYSE:LAZ ) , Amylyx Pharmaceuticals ( NASDAQ:AMLX )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday. Shares of Hello Group Inc. MOMO fell sharply during pre-market trading after reporting weak quarterly results. Hello Group posted fourth-quarter adjusted EPADS of 18 cents missing estimates ...
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., March 11, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc. ( Nasdaq: MLYS ) , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease ( CKD ) , obstructive sleep apnea ( OSA ) and other diseases driven by ...
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate - Mineralys Therapeutics ( NASDAQ:MLYS )
The Launch-HTN trial showed lorundrostat 50 mg reduced systolic blood pressure by 16.9 mmHg, with a placebo-adjusted reduction of 9.1 mmHg. The Advance-HTN trial showed lorundrostat 50 mg achieved a -7.9 mmHg placebo-adjusted reduction in systolic blood pressure.
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher - Checkpoint Therapeutics ( NASDAQ:CKPT ) , Robinhood Markets ( NASDAQ:HOOD )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 700 points on Monday. The Dow traded down 1.43% to 42,190.51 while the NASDAQ dipped 3.90% to 17,486.28. The S&P 500 also fell, dropping, 2.46% to 5,628.52.
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday - The Campbell's ( NASDAQ:CPB ) , Archer-Daniels Midland ( NYSE:ADM )
U.S. stocks were lower, with the Nasdaq Composite falling around 650 points on Monday. Shares of Redfin Corporation RDFN rose sharply during Monday's session after Rocket Companies announced it will acquire the company in an all-stock transaction valued at $12.50 per share.
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension - Mineralys Therapeutics ( NASDAQ:MLYS )
- Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction ( p-value < 0.0001 ) assessed by automated office blood pressure at week 6 - - Launch-HTN met a predefined endpoint with ...
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
RADNOR, Pa., March 07, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc. ( NASDAQ: MLYS ) , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease ( CKD ) , obstructive sleep apnea ( OSA ) and other diseases driven by ...
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET - Mineralys Therapeutics ( NASDAQ:MLYS )
RADNOR, Pa., March 07, 2025 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc.
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of ...
Ford, Skyworks Solutions, FormFactor And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Ford Motor ( NYSE:F ) , ARM Holdings ( NASDAQ:ARM )
U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 100 points on Thursday. Shares of Ford Motor Company F fell sharply in today's pre-market trading after the company said that it expects $5 billion to $5.5 billion in losses in its EV segment this year, in line ...
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Alerus Finl ( NASDAQ:ALRS ) , IMAC Hldgs ( NASDAQ:BACK )
Shares of F5, Inc. FFIV rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. F5 reported quarterly earnings of $3.84 per share, which beat the analyst consensus estimate of $3.36.
Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Telefonaktiebolaget L M ( NASDAQ:ERIC ) , Acacia Research ( NASDAQ:ACTG )
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Friday. Shares of Telefonaktiebolaget LM Ericsson ERIC fell sharply in today's pre-market trading after the company reported fourth-quarter fiscal 2024 results on Friday.
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket - Acacia Research ( NASDAQ:ACTG ) , Aclarion ( NASDAQ:ACON )
Shares of Twilio Inc. TWLO rose sharply in today's pre-market trading after the company provided preliminary financial results for the fourth quarter. After the market close on Thursday, Twilio introduced new financial expectations in a regulatory filing.
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference ...
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - Mineralys Therapeutics ( NASDAQ:MLYS )
RADNOR, Pa., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc.
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm! - Mineralys Therapeutics ( NASDAQ:MLYS )
NEW YORK, Sept. 22, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising-- NEW YORK-- ( PR NEWSWIRE ) --Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ( "Mineralys" or "the Company" ) MLYS. Investors who purchased Mineralys ...
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors - Mineralys Therapeutics ( NASDAQ:MLYS )
RADNOR, Pa., June 14, 2024 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc. MLYS, a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease ( CKD ) and other diseases driven by dysregulated aldosterone, today announced that ...
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 Dr. Olivier Litzka has resigned from the Board, effective June ...
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 - Mineralys Therapeutics ( NASDAQ:MLYS )
RADNOR, Pa., May 02, 2024 ( GLOBE NEWSWIRE ) -- Mineralys Therapeutics, Inc.
Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss
Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.
